Regulatory Story
Company Consort Medical PLC
Headline Incident at the Aesica Cramlington API Facility
Released 07:00 15-Jul-2019
Number 4554F07

RNS Number : 4554F
Consort Medical PLC
15 July 2019

Consort Medical plc


15 July 2019



Incident at the Aesica Cramlington API Facility



Consort Medical plc (LSE: CSRT) ("Consort" or "Consort Medical"), a leading developer and manufacturer of drugs and premium drug delivery devices, announces that there was a recent incident in its Cramlington manufacturing facility. While no injuries were incurred in the incident, a small area of the operating plant was damaged by the rapid thermal degradation of a chemical resulting in the expulsion of material and contamination of the facility.


The safety of our employees is our absolute priority and we have suspended all similar manufacturing processes as we determine the cause of the incident. We are being supported in this by a specialist decontamination company and process safety experts.  They will investigate the causes and compile an independent report. We are also working closely with the local regulatory authorities.


The financial impact can not be accurately quantified at this stage as it will depend on a number of factors including the timing and results of the investigation, the completion of remediation work and future production activities. However, our initial expectation is that the Group's profit is likely to be negatively impacted by between £3 million to £5 million in the current financial year due to our current estimate of the anticipated disruption from this incident. 





Consort Medical

Tel: +44 (0) 1442 867920

Jonathan Glenn - Chief Executive Officer

Paul Hayes - Chief Financial Officer

FTI Consulting

Tel: +44 (0) 20 3727 1000

Ben Atwell / Simon Conway


About Consort Medical plc


Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.


Our businesses:


Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables and ocular products, and the manufacture of devices for the point of care diagnostics market.


Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.


We employ approximately 2,000 people globally of which approximately 1,400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT).


This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.